Taiwan ACE Beads for Hepatoma Embolization Therapy
Radiopaque Microsphere (Hydrophilic Series) for Hepatoma Embolization Therapy
Sponsor: National Cheng Kung University
This NA trial investigates Cancer of Liver and is currently completed. National Cheng Kung University leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Completed NA
-
Sep 2025 — Dec 2025 [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Dec 2021 — Jul 2024 [monthly]
Completed NA
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed NA
-
Nov 2020 — Jan 2021 [monthly]
Completed NA
-
Sep 2018 — Nov 2020 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Aug 2018 — Sep 2018 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jun 2018 — Aug 2018 [monthly]
Recruiting NA
-
Sep 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Sep 2017 [monthly]
Recruiting NA
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cheng Kung University
- National Cheng-Kung University Hospital
- National Research Program for Biopharmaceuticals, Taiwan
- The Industrial Technology Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .